Benchmark Co. Maintains RXO Inc(RXO.US) With Hold Rating
BofA Securities Maintains RXO Inc(RXO.US) With Hold Rating, Maintains Target Price $30
RXO Analyst Ratings
Wolfe Research Maintains RXO Inc(RXO.US) With Sell Rating, Raises Target Price to $23
Citigroup Initiates RXO at Buy With $33 Price Target
SIG Maintains RXO Inc(RXO.US) With Sell Rating, Cuts Target Price to $16
RXO Is Maintained at Negative by Susquehanna
Susquehanna Maintains Negative on RXO, Lowers Price Target to $16
Barclays Maintains RXO Inc(RXO.US) With Buy Rating, Maintains Target Price $32
TD Cowen Maintains RXO Inc(RXO.US) With Hold Rating, Raises Target Price to $28
RXO Analyst Ratings
Oppenheimer Reiterates Outperform on RXO, Maintains $31 Price Target
Oppenheimer Maintains RXO Inc(RXO.US) With Buy Rating, Maintains Target Price $31
Barclays Maintains RXO Inc(RXO.US) With Buy Rating, Maintains Target Price $32
Barclays Sticks to Its Buy Rating for RXO, Inc. (RXO)
Jefferies Maintains RXO Inc(RXO.US) With Buy Rating, Maintains Target Price $31
BofA Securities Maintains RXO Inc(RXO.US) With Hold Rating, Cuts Target Price to $30
SIG Maintains RXO Inc(RXO.US) With Sell Rating, Raises Target Price to $20
RXO Analyst Ratings
Susquehanna Maintains Negative on RXO, Raises Price Target to $20
No Data
No Data